^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A prospective, open-label, one-arm clinical study of pemetrexed in combination with platinum-based regimens in patients with advanced non-squamous non-small cell lung cancer treated with apatinib after 4-6 cycles of chemotherapy
Excerpt:
...If the genetic test (EGFR/ALK) is an EGFR-sensitive mutation or an ALK fusion gene-positive patient, it is necessary to receive targeted therapy for the first-line treatment; if there is no mutation, it is necessary to be a first-line patient; 4. ...
Trial ID:
Source:
Title:
A national, multicenter, prospective, real-world study of first-line treatment of advanced or metastatic non-small-cell lung cancer with carrizumab combined with pemetrexed plus platinum
Excerpt:
...Histopathological examination confirmed non-small cell lung cancer,EGFR mutation or ALK gene rearrangement was negative; 3. ...
Trial ID:
More C2 evidence
Source:
Title:
A retrospective study for the predictors of the outcomes of pemetrexed plus platinum chemotherapy in patients with advanced non-small cell and non-squamous lung cancer
Excerpt:
...The mutation (alteration) status of EGFR, ALK, ROS1, RET, HER2, BRAF and MET genes of the subjects is unknown or no therapeutic gene mutation (alteration) is found in the test; 4. ...
Trial ID:
Source:
Title:
Study evaluating two maintenance strategies (continuous and according to the response of chemotherapy in advanced lung cancer) Etude évaluant deux stratégies de maintenance (maintenance de continuation et maintenance en fonction de la réponse à la chimiothérapie) dans le cancer du poumon de stade avancé
Excerpt:
...- non-squamous NSCLC histologically or cytologically confirmed - Stage IV with a cytologically or histologically confirmation for an unique metastasis - No EGFR activating mutation or undeterminated EGFR mutational status - At least one measurable lesion - Age between 18 and 70 - PS 0 or 1 - CBNPC prouvé cytologiquement ou histologiquement en privilégiant autant que possible l'obtention d'une preuve histologique (recherche d'une mutation du gène de l'EGF-R et analyse des biomarqueurs), à prédominance non-épidermoïde : adénocarcinome, carcinome à grandes cellules, CBNPC sans différenciation déterminée (classé "NOS : not otherwise specified") - Stade IV (7ème classification TNM UICC 2009 [33]) avec nécessité d'une preuve cytologique ou histologique en cas de lésion métastatique unique facilement accessible. ...
Trial ID:
Source:
Title:
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
Excerpt:
...- Patients with known EGFR-activating mutations or ALK rearrangements should have received treatment with a targeted kinase inhibitor (e.g., erlotinib, crizotinib) and...
Trial ID:
Source:
Title:
Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.
Excerpt:
...Metastatic non-squamous non-small cell lung cancer with EGFR mutations confirmed by histological or cytological examination; 4....
Trial ID:
Source:
Title:
The Clinical Effect of EGFR-TKI Combined with Chemotherapy on Patients with EGFR Multiple Mutation
Excerpt:
...EGFR sensitive mutation positive, and EGFR T790M negative; 9. ...
Trial ID:
Source:
Title:
A prospective, real-world clinical study of the efficacy and safety of camrelizumab combined with pemetrexed and bevacizumab in the treatment of newly diagnosed driver-gene-negative advanced non-squamous non-small cell lung cancer
Excerpt:
......
Trial ID:
Less C2 evidence
Source:
Title:
Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405)
Published date:
06/20/2022
Excerpt:
Patients with treatment including pemetrexed exhibited significantly longer OS in comparison to those without pemetrexed; the median OS in the pemetrexed + and pemetrexed– patients were 40.7 months and 28.0 months, respectively (0.55 of HR [95% CI: 0.38–0.80, p = 0.0020])....Sequential treatment including pemetrexed against EGFR-mutated NSCLC might be associated with a better outcome.
DOI:
https://doi.org/10.1007/s10147-022-02193-x
Source:
Title:
Efficacy and Safety of Intrathecal Pemetrexed Combined with Dexamethasone for Treating TKI-failed Leptomeningeal Metastases from EGFR-mutant NSCLC-A Prospective Open-label Single-arm Phase I/II Clinical Trial (unique identifier: ChiCTR1800016615)
Published date:
05/11/2021
Excerpt:
EGFR-mutant NSCLC patients with LM who had failed tyrosine-kinase inhibitors (TKIs) were recruited….The RD observed in the Phase I study was 50 mg pemetrexed....The clinical response rate was 84.6% (22/26). The median OS of all patients was 9.0 months (n=30, 95%CI, 6.6-11.4 months).
DOI:
10.1016/j.jtho.2021.04.018
